Market Overview

Express Scripts Outlook Improves Amid Tax Reform, CVS-Aetna Deal

Express Scripts Outlook Improves Amid Tax Reform, CVS-Aetna Deal
Related ESRX
Jim Cramer Weighs In On Abiomed, Express Scripts And Lockheed Martin
Benzinga's Top Upgrades, Downgrades For September 18, 2018

Recent developments in the healthcare space, including the proposed merger between CVS Health Corp (NYSE: CVS) and Aetna Inc (NYSE: AET), bodes well for Express Scripts Holding Company (NASDAQ: ESRX).

The Analyst

Bernstein's Lance Wilkes upgraded Express Scripts from Underperform to Market Perform with a price target boosted from $51 to $65.

The Thesis

The most compelling factor supporting an upgrade of Express Scripts' stock is tax reform, Wilkes said in a Wednesday note. Tax reform and the potential for a reduction in corporate tax rate would boost Express Scripts' after-tax earnings by around 11 percent over time, but with a near-term higher saving of about 23 percent, the analyst said. 

Second, the CVS/Aetna merger would benefit Express Scripts as health plan clients will look to "move away from a perceived competitor," the analyst said. This would impact medium-sized health plans for the most part — a segment in which Express Scripts is smaller than CVS, Wilkes said. While this segment is lower margin than the company's employment segment, it would nevertheless be additive to earnings at the expense of margins, the analyst said.

Finally,, Inc. (NASDAQ: AMZN)'s potential entry into the pharmaceutical space would likely prompt a large player like Walgreens Boots Alliance Inc (NASDAQ: WBA) to acquire Express Scripts in a defensive move, Wilkes said. Although there is a low probability of this occurring, it nevertheless serves as an upside opportunity for the stock, the analyst said. 

Price Action

Shares of Express Scripts gained more than 0.5 percent early Wednesday morning.

Related Links:

Analyst: Fintech Is A Big Winner From Tax Reform, 5 Stocks To Play

Baird: The Potential Restaurant Winners From A New Tax Bill

Photo courtesy of Express Scripts.


Latest Ratings for ESRX

Sep 2018Credit SuisseDowngradesOutperformNeutral
Jul 2018BairdDowngradesOutperformNeutral
May 2018BarclaysMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for ESRX
View the Latest Analyst Ratings

Posted-In: Amazon Pharmacy Bernstein healthcare Lance WilkesAnalyst Color Upgrades Price Target Analyst Ratings Best of Benzinga


Related Articles (AMZN + AET)

View Comments and Join the Discussion!

Latest Ratings

VIABImperial CapitalUpgrades29.0
CDNSJP MorganUpgrades51.0
EBAYRBC CapitalDowngrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

OPEC Meeting Ends With An Extension And An Agreement With Russia

First Solar Up On Guidance Issuance, Unveils Series 6 Module